英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
accessibilite查看　accessibilite　在百度字典中的解释百度英翻中〔查看〕
accessibilite查看　accessibilite　在Google字典中的解释Google英翻中〔查看〕
accessibilite查看　accessibilite　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Evidence-based treatments for eosinophilic esophagitis: insights for . . .
    Formulations of STC originally designed for asthma therapy are suboptimal for EoE treatment, with new effervescent orodispersible tablets and viscose formulations designed to coat the esophageal mucosa providing increased effectiveness at reduced doses Pharmacological treatments for eosinophilic esophagitis: current options and emerging
  • How New Drug Approvals are Reshaping Treatment for Eosinophilic Esophagitis
    The FDA has approved two medications for the treatment of eosinophilic esophagitis (EoE)—the first oral medication tailored for adults and the exclusive therapeutic option for children Evan Dellon, MD, MPH, internationally known for his work with EoE, and colleagues continue to focus on optimizing usage for effective, personalized outcomes
  • First FDA-Approved Treatment for Eosinophilic Esophagitis Has Roots in . . .
    The first Food and Drug Administration approval of a treatment for eosinophilic esophagitis, This scientific foundation, among many other factors, led Regeneron Pharmaceuticals Inc of Tarrytown, New York, and Sanofi of Paris to begin testing one of their drugs for the treatment of EoE The drug, a monoclonal antibody called dupilumab
  • Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 Years of Age
    A gene expression panel is accurate for diagnosis and monitoring treatment of eosinophilic esophagitis in adults Clin Transl Gastroenterol 2017;8(2 A F , G D Y , J M ) — both in New York
  • FDA Approves EOHILIA (budesonide oral suspension) - Takeda
    EOHILIA is indicated for 12 weeks of treatment in adult and pediatric patients 11 years of age and older with eosinophilic esophagitis (EoE) EOHILIA has not been shown to be safe and effective for the treatment of EoE for longer than 12 weeks Important Safety Information Contraindications
  • Eosinophilic esophagitis: promising therapy, biomarkers, and assessment . . .
    New diagnostic, monitoring, and treatment approaches are available for eosinophilic gastrointestinal diseases, including breakthroughs in eosinophilic esophagitis with new biologics and biomarkers The recent approval of dupilumab for treatment of eosinophilic esophagitis (EOE), research into better biomarkers, and the anticipated availability
  • The New Therapeutic Frontiers in the Treatment of Eosinophilic . . . - PubMed
    Eosinophilic esophagitis (EoE) is a multifaceted disease characterized by a wide heterogeneity of clinical manifestations, endoscopic and histopathologic patterns, and responsiveness to therapy The New Therapeutic Frontiers in the Treatment of Eosinophilic Esophagitis: Biological Drugs Int J Mol Sci 2024 Jan 30;25(3):1702 doi: 10 3390
  • FDA Grants Orphan Drug Designation to ‘1104, First-In-Class Peptide for . . .
    The FDA has granted Orphan Drug Designation (ODD) to ‘1104, a first-in-class immune-resetting peptide (Revolo Biotherapeutics) designed to treat eosinophilic esophagitis (EoE) The ODD offers support in developing potential new medicines, treatment, and diagnostic tools to prevent rare conditions that impact fewer than 200,000 individuals in
  • Eohilia Gets FDA Approval for Swallowing Disorder Eosinophilic Esophagitis
    It’s approved to treat patients 11 years and older with eosinophilic esophagitis (EoE) and is intended to be taken twice daily for a three-month course of treatment, the drugmaker Takeda said in
  • Etrasimod as a treatment for eosinophilic oesophagitis (VOYAGE): a . . .
    Etrasimod led to sustained histological and endoscopic improvements in eosinophilic oesophagitis over 52 weeks, symptom improvement in patients without dilation, and was well tolerated This trial provides the first evidence that targeting the S1P pathway can improve disease activity in patients with eosinophilic oesophagitis and that S1P receptor modulation is a viable treatment target for





中文字典-英文字典  2005-2009